CERo Therapeutics Holdings, Inc.
CERO
$9.46
$0.232.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -859.92% | 115.89% | -72.66% | -6.48% | -81.77% |
| Total Depreciation and Amortization | -5.31% | -4.27% | 1.36% | 1.77% | 1.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 112.35% | -1,628.27% | 112.48% | 9.48% | -1,544.06% |
| Change in Net Operating Assets | -105.68% | 33.50% | 60.95% | 163.66% | -595.93% |
| Cash from Operations | -188.66% | 44.17% | 22.01% | 30.37% | -428.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | 32.21% | -1.07% | -657.87% | -147.82% |
| Issuance of Common Stock | -- | -- | -5.61% | -59.75% | 356,184.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 136,635.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 179.66% | -19,545.99% | -- | -- |
| Cash from Financing | 325.16% | -40.32% | -3.84% | -63.80% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,633.90% | 80.10% | 71.80% | -145.54% | 316.25% |